Compare · BOAC vs TENK
BOAC vs TENK
Side-by-side comparison of Bluescape Opportunities Acquisition Corp. (BOAC) and TenX Keane Acquisition (TENK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BOAC and TENK operate in Blank Checks (Finance), so they compete in similar markets.
- BOAC carries a market cap of $743.4M.
BOAC
Bluescape Opportunities Acquisition Corp.
Bluescape Opportunities Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Dallas, Texas.
Latest BOAC
- SEC Form SC 13G/A filed by Bluescape Opportunities Acquisition Corp. (Amendment)
- Bluescape Opportunities Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 25-NSE filed by Bluescape Opportunities Acquisition Corp.
- Bluescape Opportunities Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Bluescape Opportunities Acquisition Corp. Will Redeem its Public Shares and Will Not Consummate an Initial Business Combination
- SEC Form 10-Q filed by Bluescape Opportunities Acquisition Corp.
- SEC Form 10-Q/A filed by Bluescape Opportunities Acquisition Corp. (Amendment)
- SEC Form 10-K/A filed by Bluescape Opportunities Acquisition Corp. (Amendment)
- SEC Form 10-Q filed by Bluescape Opportunities Acquisition Corp.
- SEC Form 10-K filed by Bluescape Opportunities Acquisition Corp.
Latest TENK
- Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition
- SEC Form 4 filed by Director Dutia Suren G
- SEC Form 4 filed by Director Holubiak Myron Z
- SEC Form 4 filed by Chief Medical Officer Czuczman Myron
- SEC Form 4 filed by Chief Executive Officer Mazur Leonard L
- SEC Form 4 filed by Chief Financial Officer Bartushak Jaime
- SEC Form 4 filed by Director Mcgrath Dennis M
- SEC Form 4 filed by Large owner Citius Pharmaceuticals, Inc.
- SEC Form 4 filed by Director Webb Carol
- SEC Form 3 filed by new insider Dutia Suren G